Many compounds are oxidized by haem enzymes, such as peroxidases and cytochromes P450, to highly reactive intermediates that function as enzyme inactivators. To evaluate the potential of arylhydrazides as selective metabolically activated peroxidase inhibitors, the mechanism of HRPC (horseradish peroxidase isoenzyme C) inhibition by BZH (benzhydrazide) was investigated in detail. No oxygen consumption was detected in BZH solutions at pH 7.0-12.0, but addition of HRPC resulted in significant O 2 uptake above pH 8.0, indicating that the enzyme catalyses BZH oxidation. Addition of H 2 O 2 to HRPC plus BZH activates the latter as an inhibitor. This involves the three-electron oxidation of BZH in one-electron steps by the peroxidase catalytic intermediates, Compounds I and II, to produce a benzoyl radical that covalently alters the active site and inhibits peroxidase activity. Alternatively, the benzoyl radical could be produced by di-imide (NH = NH) elimination from the BZH radical. Production of Compound III (oxyperoxidase) followed by p-670 (m/z = 583, biliverdin-like derivative) was observed for HRPC incubated with excess H 2 O 2 , and the addition of BZH resulted in an increase in the rate of p-670 production. BZH is an inefficient inhibitor of HRPC with a K I of 80 µM, an apparent inactivation rate constant (k inact ) of 0.035 min −1 , and an IC 50 of 1.0 mM. This prompted the investigation of HRPC inactivation by a series of related arylhydrazides with known binding affinities for HRPC. The hydrazide with the highest affinity (2-naphthoichydrazide; K d = 5.2 µM) was also found to be the most effective inhibitor with K I , k inact and IC 50 values of 14 µM, 0.14 min −1 and 35 µM, respectively.
INTRODUCTION
Arylhydrazines are oxidized by haem peroxidases to highly reactive radical species that can be incorporated at the active site [1] . Covalent haem modification by hydrazines (R-NH-NH 2 ) has been employed as a method for probing active-site topology in a number of peroxidases [1] [2] [3] [4] [5] [6] [7] . Hydrazides (R-CO-NH-NH 2 ) are related compounds, and are known to be peroxidase inhibitors [8] [9] [10] [11] [12] [13] . Several hydrazine and hydrazide derivatives have been used therapeutically, including isoniazid [INH (isonicotinic hydrazide) tuberculosis antibiotic], iproniazid (tranquilizer), isocarboxazid, mebanazine, phenelzine (monoamine oxidase inhibitors), hydralazine (antihypertensive) and PHZ (phenylhydrazine; control of polycythemia vera). However, many of these compounds are no longer in use as drugs due to the severe side effects resulting from their bioactivation, which include haemolysis, liver damage, lupus erythematosus and base-pair mutation [14] [15] [16] [17] [18] .
Hydrazines and hydrazides are metabolically activated inhibitors. Following enzymic activation, metabolically activated inhibitors are released from the active site and can rebind the same enzyme or a different biomolecule, thereby leading to inactivation [19] . Their unwanted side effects may be due to low specificity of either the prodrug or the activated form, resulting in activation by, or inactivation of, non-target enzymes. Specificity depends on both the binding affinity and the reactivity of the activated inhibitor. HRPC (horseradish peroxidase isoenzyme C) is efficiently inactivated by PHZ [2] , but since PHZ undergoes 1 To whom correspondence should be addressed (e-mail english@vax2.concordia.ca and david percival@merck.com).
auto-oxidation at pH 7 to produce superoxide [20] , it is unsuitable as a therapeutic [11] . In contrast, auto-oxidation of INH occurs at a much lower rate at pH 7 [11] . Following activation by peroxidase/catalase (KatG) of Mycobacterium tuberculosis [21] , activated INH reacts with the cofactor of enoyl reductase to form an inhibitor that has been identified as isonicotinic-acylnicotinamide adenine dinucleotide [21, 22] . Despite its severe side effects, including autoimmune syndromes (e.g. lupus, erythamatosus-like syndrome, rheumatic syndrome) and allergies, INH is still the primary drug worldwide for the treatment of tuberculosis [23] . The side effects observed for INH serve to illustrate the problems associated with the use of metabolically activated hydrazides as drugs. An investigation of the structural factors that control the efficiency of peroxidase inhibition by arylhydrazides is clearly necessary to assess their potential as therapeutic agents or as tools to define the activities of specific peroxidases in vivo. For example, a selective inhibitor would be of use in elucidating the role of MPO (myeloperoxidase) in inflammatory tissue damage. Although MPO-deficient mice have provided valuable information on the role of MPO in host defence and protection from atherosclerosis in vivo, extrapolation of these results from the mouse model to humans is complicated [24] .
Since HRPC is an archetypical peroxidase its inactivation by BZH (benzhydrazide), the simplest arylhydrazide, was investigated in detail. Additionally, HRPC inactivation by a series of monosubstituted arylhydrazides (Figure 1 ) was examined. IC 50 as well as K I and k inact values were determined to identify the factors necessary for the effective inhibition of HRPC. The results are compared with those reported for arylhydrazide inhibition of MPO [8] [9] [10] .
MATERIALS AND METHODS
Lyophilized grade I HRPC was obtained from Roche Molecular Biochemicals. All hydrazides were purchased from Lancaster Synthesis (Easgate, Lancs., U.K.) with the exception of 3-hydroxybenzhydrazide and 4-hydroxybenzhydrazide, which were from Aldrich. PHZ was from Sigma. All reagents were of the highest quality available and were used without further purification.
Determination of K I and k inact values for inhibition of HRPC HRPC (10 nM) was preincubated at 25
• C with 1 mM H 2 O 2 and 0-10 mM hydrazide (0-5 mM for BZH) in 100 mM sodium phosphate buffer, pH 7.0. Aliquots were taken and tested for activity at time points between 0.5 and 120 min. The assay solution (200 µl) contained 5 mM guaiacol, the chromogenic donor substrate, and 1 mM H 2 O 2 in 100 mM sodium phosphate buffer, pH 7.0, and the final HRPC concentration was 1 nM. HRPC activity at 25
• C was measured spectrophotometrically for 1 min at 450 nm with a SpectraMax 190 (Molecular Devices) microtitre plate reader. The percent remaining activity (ratio of initial velocity of guaiacol oxidation by treated and untreated HRPC) was plotted against preincubation time, and pseudo-firstorder rate constants for HRPC inactivation (k obs , min −1 ) at each hydrazide concentration were calculated from least-squares fits to:
where y, a and b represent HRPC activity at time t, t = ∞ (minimum activity) and t = 0 (maximum activity) respectively. The least-squares fit of eqn (2) 
Determination of IC 50 values for HRPC inhibition HRPC (10 nM) was preincubated at 25
• C in 100 mM sodium phosphate, pH 7.0, containing 1 mM H 2 O 2 and 0.001-50 mM hydrazide for 1 min prior to assaying activity. Guaiacol-oxidizing activity was assayed as described above, and the percent remaining activity was plotted against hydrazide concentration [I] to generate titration curves that were fit to:
where y is the percentage remaining activity, a is activity at 
Isolation and characterization of modified haems from HRPC
A haem-extraction protocol described by Ator and Ortiz de Montellano [2] was used with minor modifications. Sufficient inhibitor (I = 2-6 mM BZH or I = 3-8 mM PHZ depending on the I/H 2 O 2 ratio; see Figure 3E , below) and H 2 O 2 (3-6 mM H 2 O 2 depending on the I/H 2 O 2 ratio; see Figure 3E , below) were added to 2.5-ml solutions of 20 µM HRPC to inhibit its guaiacoloxidizing activity within 2 min. Following a 10-min incubation at room temperature the inactivated HRPC solutions were desalted by gel filtration on 9-ml G-25 columns (PD10; Amersham Biosciences). The protein-containing eluates (approx. 3.5 ml) were then acidified with 1 ml of glacial acetic acid saturated with NaCl, and the haems were extracted with three 3-ml portions of ethyl acetate. The combined organic layers were washed with water, evaporated to dryness under a stream of argon, and dissolved in 250 µl of HPLC solvent A (methanol/water/acetic acid, 68:32:10 by vol.). Aliquots were separated by isocratic reversed-phase HPLC with solvent A on a Hewlett Packard 1090 HPLC with a Vydac C 18 column (1 mm × 250 mm) that was directly connected to the electrospray ionization source of a ThermoFinnigan SSQ 7000 single quadrupole mass spectrometer. The needle voltage was 4.5 kV, the capillary temperature was 210
• C, and online acquisition of mass spectra was performed at a rate of 5 s/scan.
RESULTS

Oxidation of BZH catalysed by HRPC
Under aerobic conditions at pH 10.0, HRPC is partially converted to a low-spin haem species in the presence of 25 mM BZH as evidenced by the presence of peaks at 543 and 577 nm in the difference spectra ( Figure 2A , dashed line). Compound III [HRPC (Fe  II O 2 ) , oxyperoxidase] exhibits absorption maxima at these wavelengths [26] . Since the presence of 50 nM catalase did not eliminate Compound III formation (results not shown), it is not derived from the reaction of HRPC with H 2 O 2 generated in solution. O 2 consumption is observed and increases with pH in solutions containing both HRPC and BZH ( Figure 2B ). However, in solutions containing BZH (e.g. pH 12.0 data, Figure 2B, Figure 3C ) and (iii) covalent modification since the removal of low-molecular-mass species via gel filtration did not restore activity (results not shown). The rate of HRPC inactivation increased with enzyme concentration (Figure 3D ), indicating that an activated form of BZH is released and rebound prior to inactivation. This distinguishes metabolically activated inhibitors from mechanism-based inhibitors, which are not released prior to enzyme inactivation. The observation that the inactivation efficiency of HRPC increases as the molar ratio of BZH/H 2 O 2 decreases (0.5 > 1 > 2; Figure 3E ) suggests that multiple oxidation steps are required to generate the activated inhibitor, and provides further evidence that BZH is a metabolically activated inhibitor. The rate of inactivation (k obs ) for a second aliquot of HRPC (100 nM) added to an incubation of 100 nM HRPC with 500 µM BZH and 500 µM H 2 O 2 , following complete inactivation (1 h), was identical to that of the first aliquot, indicating that the activated BZH species is labile. 
Isolation of modified haems resulting from HRPC inactivation by BZH and PHZ
The prosthetic group was extracted from untreated HRPC (control, Figure 5A ), and HRPC inactivated at BZH/H 2 O 2 molar ratios of 2 ( Figure 5B ), 1 (results not shown) and 0.5 ( Figure 5C ). The extracts were separated by reversed-phase HPLC and analysed by MS. The absorption spectra (Figure 6 peak in the control; Figure 5A ) and 5 (m/z 720) exhibited similar absorption spectra (Figures 6B-6D ). The spectra of peak 4 from BZH/H 2 O 2 -inactivated HRPC ( Figure 6C ) and untreated HRPC were identical, and were assigned to native haem. Based on their m/z values and the haem adducts previously observed for HRPC inactivation by PHZ [2] , peaks 2 and 5 were assigned to hydroxyl-and benzoyl-haem, respectively. In contrast to peak 1, which increased in intensity with decreasing BZH/H 2 O 2 ratios (2 < 1 < 0.5), peaks 2 and 5 were maximal in the BZH/H 2 O 2 = 2 sample ( Figure 5B ). Peaks 3, 6 and 7 ( Figure 5B ) exhibited absorption spectra similar to native haem ( Figure 6C ) but were not identified by electrospray ionization MS. Peak 7 was also observed in the control extract ( Figure 5A ), which identifies it as an impurity in HRPC.
Haems were also extracted from HRPC exposed to PHZ/H 2 O 2 at ratios of 2 and 0.5 (results not shown). These were identified as hydroxyl-(m/z 632), native (m/z 616) and phenyl-protoporphyrin IX haem (m/z 692), consistent with the previous report of 8-hydroxymethyl-haem and δ-meso-phenyl-haem formation in PHZ turnover by HRPC and H 2 O 2 [2] .
Kinetics of HRPC inactivation by monosubstituted arylhydrazides plus H 2 O 2
The 21 arylhydrazides listed in Table 1 exhibit similar kinetic parameters for the time-dependent inactivation of HRPC as BZH ( Figure 3B ). The measurement of enzyme activity by transfer of aliquots from preincubations to assay conditions resulted in the presence of 0-1 mM and 0-5 mM hydrazide in the activity assays for the determination of K I and k inact , and IC 50 values, respectively. However, the ability of guaiacol (5 mM in the assays) to provide complete protection against the inactivation of HRPC by an equimolar concentration of BZH ( Figure 3C ) demonstrates that competition between hydrazide and guaiacol for oxidation by HRPC in the assays is not a significant source of error.
DISCUSSION
Oxidation of BZH catalysed by HRPC
The proposed reactions involved in HRPC-catalysed O 2 consumption in BZH solutions are summarized in Scheme 1. In the model proposed for MPO-catalysed oxidation of 4-NH 2 -BZH (4-aminobenzhydrazide), the hydrazide undergoes free-metal-ioncatalysed oxidation to produce H 2 O 2 , which is subsequently consumed in the MPO-catalysed oxidation of 4-NH 2 -BZH [10] . Free-metal-ion-catalysed oxidation has also been proposed for INH and PHZ [13, 28, 29] but no O 2 consumption was observed here in BZH solutions in the absence of HRPC ( Figure 2B ). O 2 consumption was observed in solutions containing both BZH and HRPC ( Figure 2B ). As proposed in Scheme 1, the BZH anion (see below) is oxidized by the ferric enzyme to give HRPC (Fe  II ) are intermediates in the latter process, which regenerates resting HRPC(Fe III ) (Scheme 1 Figure 2B ) increase with pH, suggesting that the donor to HRPC(Fe III ) is BZH − rather than its neutral form (pK a = 12.5 [32] ). Given that the reduction potential, E o , of HRPC(Fe III/II ) is more negative at higher pH [33] , HRPC(Fe II CO) formation would probably decrease with increasing pH if unionized BZH were the reductant. The negligible O 2 consumption at pH 7.0 ( Figure 2B) shows that BZH oxidation and free-radical generation is minimal at physiological pH. 4-NH 2 -BZH oxidation by MPO in the absence of added H 2 O 2 is also minimal at pH 7.0 and increases above this pH [10] . In contrast, PHZ undergoes both extensive auto-oxidation and haem-catalysed oxidation at physiological pH [20, 29] . Auto-oxidation should not impede the development of hydrazides as potential therapeutics.
However, recent results have demonstrated that the therapeutic effects of INH are due to its oxidation via the superoxide pathway rather than the peroxidase pathway of KatG [13, 28] . Therefore, further work on hydrazide-dependent free radical generation catalysed by different peroxidases is a necessary step in assessing the potential of these compounds as therapeutic agents.
HRPC inactivation by H 2 O 2
Approx. 0.12 µmol of O 2 was produced during the consumption of 0.43 µmol of H 2 O 2 (approx. 300 molar equivalents) by 1.5 nmol Figure 4C ).
HRPC inactivation by BZH/H 2 O 2
Inactivation of HRPC by BZH/H 2 O 2 probably involves covalent modification of the enzyme since removal of low-molecularmass species by gel filtration did not restore activity (results not shown). The correlation between HRPC concentration and the rate of enzyme inactivation ( Figure 3D ) suggests that release and rebinding of an activated BZH species occurs prior to inactivation, as expected for a metabolically activated inhibitor. This is supported by the observations that inactivation is timedependent ( Figures 3A and 3B ) and that equimolar guaiacol provided complete protection against inactivation ( Figure 3C ).
The isolation of hydroxyl-haem (m/z 632) and benzoyl-haem (m/z 720) adducts provides further evidence for covalent modification of HRPC by BZH/H 2 O 2 . Nonetheless, native haem was the predominant species isolated from BZH/H 2 O 2 -inactivated HRPC ( Figure 5 ). The yield of hydroxyl-protoporphyrin IX haem was dramatically higher in HRPC samples treated with PHZ/H 2 O 2 (results not shown) than with BZH/H 2 O 2 ( Figure 5 ). It is possible that HRPC inactivation by BZH/H 2 O 2 is due predominantly to modification of the polypeptide rather than the haem, and a phenyl-protein adduct was detected (but not localized) in PHZ/H 2 O 2 -inactivated HRPC [2] . Modification of protein residues around the active site by benzoyl adduct formation would result in diminished access to reducing substrates but not to H 2 O 2 , thus accelerating the formation of Compound III and p-670, as observed in the presence of BZH/H 2 O 2 ( Figure 4C ).
Based on their masses, absorption spectra ( Figure 6 ), and the reported haem shielding by the polypeptide that directs reactants to the δ-meso-position [2, 38] , the modified haems extracted from BZH/H 2 O 2 -treated HRPC (Scheme 2, compounds 9 and 10) are assumed to be δ-meso-benzoyl-haem (m/z 720) and 8-hydroxymethyl-haem (m/z 632). The growth and decay of 825-nm absorption during the inactivation of HRPC by phenylethylhydrazine and H 2 O 2 was attributed to the transient formation of an isoporphyrin cation following attack of the phenylethyl radical on the haem of Compound II [3] Formation of hydroxyl-haem (compound 9) is also shown in Scheme 2 and is based on the mechanism proposed for HRPC inactivation by PHZ/H 2 O 2 [2] . Abstraction of a hydrogen atom from the haem (compound 6) by the benzoyl radical (compound 5) results in a carbon-centred radical (compound 7) that is oxidized by the Fe IV = O centre. Subsequent addition of water to the cation leads to the formation of compound 9. Water rather than O 2 was observed to be the source of the hydroxyl group in the HRPC/ PHZ/H 2 O 2 reaction [2] .
Two mechanisms for benzoyl radical generation are considered (Scheme 2). Following mechanism 1, proposed for INH activation [39] , one-electron oxidation of BZH by Compound I (or Compound II) yields the BZH
• radical (compound 2) which eliminates NH = NH (di-imide) to produce the benzoyl radical (compound 5). In the second mechanism, based on that proposed for PHZ activation [2] , BZH is oxidized in three single-electron steps by Compounds I/II to the diazene radical (compound 4). N 2 release from compound 4 gives the benzoyl radical (compound 5), which covalently modifies the peroxidase. Both mechanisms could be operative in HRPC inactivation by BZH/H 2 O 2 for the following reasons. (i) Oxidation of BZH (compound 1) would compete with oxidation of the diazene (compound 3) or inactivation by the free benzoyl radical (compound 5) so that the efficiency of inactivation would decrease at higher BZH/H 2 O 2 ratios as observed in Figure 3 shown). In fact, the peroxy radical, formed by the addition of O 2 to the acyl radical, has been reported as a major product of INH oxidation by HRPC [13] . Figure 2 ). The relatively low K I value for 2-NZH (2-naphthoichydrazide; 0.014 mM, Table 1) suggests that the diazene (compound 3) and/or the naphthoyl radical (compound 5) derived from 2-NZH bind HRPC more tightly than those of the other hydrazides, which would be consistent with the low K d (5.2 µM, Table 1 ) of 2-NZH. With the exception of 3-NO 2 -BZH, the IC 50 values for the meta-and para-substituted hydrazides vary by only 3-fold or less. Substituents in the ortho-position result in increased IC 50 values (Table 1) , which is likely to be due to the confined active site of HRPC [38] .
The high IC 50 and low k inact values for HRPC inhibition by the aromatic hydrazides in Table 1 suggest that the design of an HRPC-selective hydrazide inhibitor will be challenging. Tight inhibitor binding is important since the additional phenyl ring of 2-NZH lowers the IC 50 and K d values by 28-and 23-fold, respectively, relative to BZH. Addition of polar ring substituents will be desirable for solvation of larger aromatic hydrazides and selectivity will be promoted by the placement of the ring substituents. For example, substituents ortho to the hydrazide group are expected to decrease HRPC selectivity (Table 1) .
